
|Articles|March 12, 2009
Roche closes $46.8 billion Genentech deal
Zurich, Switzerland - Roche Holding AG has sealed a deal with Genentech to buy the 44 percent of the company that it doesn't already own for $95 a share, CNNMoney.com reports.
Advertisement
Zurich, Switzerland
- Roche Holding AG has sealed a deal with Genentech to buy the 44 percent of the company that it doesn't already own for $95 a share, CNNMoney.com reports.
This agreement ends an eight-month battle, in which Genentech repeatedly rejected Roche’s offer. The price was negotiated from $93 per share to $95, which a Genentech board member says is a fair offer to shareholders, according to CNNMoney.com.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
FDA Clears IND Application of Recludix’s Oral STAT6, REX-8756
3
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
4
Practical Approaches to Managing Atopic Dermatitis With Topical Therapies
5

















